Inventor · disambiguated record
Philippe Michel Rene Bouillot
Also filed as: BOUILLOT PHILIPPE MICHEL RENE
1 granted patent·13 pending applications·0 citations·filing 2013–2025
14Inventor score
Top patents by PatentIndex Score
14 records- 0171US2025041266A1S1p modulator immediate release dosage regimenNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0267US2025073203A1Immunosuppressant formulationNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0367US2025084034A1Immunosuppressant formulationsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0458US12071402B2Immunosuppressant formulationsNOVARTIS AG·Filed 2021·Granted Aug 27, 2024·0 cites·12 claims
- 0555US2021161860A1Immunosuppressant formulationNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0652US2022016076A1Sip modulator immediate release dosage regimenNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0749US2020199069A1Immunosuppressant formulationsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0847US2019328705A1Immunosuppressant formulationNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0946US2019054065A1Sip modulator immediate release dosage regimenNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1045US2025332110A1Pharmaceutical formulations of an androgen receptor-targeting protein degraderARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 1144US2018207128A1Immunosuppressant formulationNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1235US2013273161A1Immunosuppressant formulationsBOUILLOT PHILIPPE MICHEL RENE·Filed 2013·Application pending·0 cites
- 1333US2017027907A1Sip modulator immediate release dosage regimenLEGANGNEUX ERIC·Filed 2015·Application pending·0 cites
- 1429US2017027906A1Immunosuppressant formulationBOUILLOT PHILIPPE MICHEL RENE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Philippe Michel Rene Bouillot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →